ArcherDX is bringing it up a notch through a new collaboration with Ayala Pharmaceuticals, a clinical stage precision oncology company. 

In the agreement, Denver, CO-based ArcherDX will develop companion diagnostics with Ayala, that will target cancers bearing Notch activating mutations and fusions. 

Ayala is broadly developing its product candidates, AL101 and AL102, gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala's lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations

"Working closely with biopharma partners to help bring biomarker-driven therapies to individuals diagnosed with cancer is central to our mission to improve access to genomic-based medicine,” Jason Myers, Co-Founder and CEO of ArcherDX, said in a release. “Partnerships with progressive companies such as Ayala who can leverage our unique ability to provide companion diagnostic solutions from both tissue and blood-based specimens and deploy them at scale as in-vitro diagnostics to laboratories around the world is essential to achieving this mission.”

The collaboration with Ayala comes just a few months after ArcherDx closed $60 million in a series B round. In 2018, the company raised $35 million in a series A round.

However, ArcherDx reached one of its most significant milestones earlier this year by receiving a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.